Evidence map›Paper›PMID 29416016›Full record

ArticleCell death & disease2018

Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death.

Stefano Thellung, Beatrice Scoti, Alessandro Corsaro, Valentina Villa, Mario Nizzari, Maria Cristina Gagliani, Carola Porcile, Claudio Russo, Aldo Pagano, Carlo Tacchetti and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 50 citations in OpenAlex.

  1. CpG oligodeoxynucleotide reduces PrPMolecules and cells · 2026
    Article
  2. Article
  3. Utilizing nanotechnology to diagnose and treat central nervous system disorders.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Stefano ThellungSection of Pharmacology, Department of Internal Medicine (DiMI), and Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy.
Beatrice ScotiSection of Pharmacology, Department of Internal Medicine (DiMI), and Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy.
Alessandro CorsaroSection of Pharmacology, Department of Internal Medicine (DiMI), and Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy.
Valentina VillaSection of Pharmacology, Department of Internal Medicine (DiMI), and Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy.
Mario NizzariSection of Pharmacology, Department of Internal Medicine (DiMI), and Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy.
Maria Cristina GaglianiSection of Human Anatomy, Department of Experimental Medicine (DIMES), School of Medicine, University of Genova, Genova, Italy.
Carola PorcileDepartment of Health Sciences, University of Molise, Campobasso, Italy.
Claudio RussoDepartment of Health Sciences, University of Molise, Campobasso, Italy.
Aldo PaganoSection of Human Anatomy, Department of Experimental Medicine (DIMES), School of Medicine, University of Genova, Genova, Italy.
Carlo TacchettiCentro Imaging Sperimentale, IRCCS Istituto Scientifico San Raffaele, Milano, Italy.
Katia CorteseSection of Human Anatomy, Department of Experimental Medicine (DIMES), School of Medicine, University of Genova, Genova, Italy.
Tullio FlorioSection of Pharmacology, Department of Internal Medicine (DiMI), and Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy. tullio.florio@unige.it.
University of Genoa · ITUniversity of Molise · ITOspedale Policlinico San Martino · ITVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the "gain-of-toxicity mechanism", neuronal loss during cerebral proteinopathies is caused by accumulation of aggregation-prone conformers of misfolded cellular proteins, although it is still debated which aggregation state actually corresponds to the neurotoxic entity. Autophagy, originally described as a variant of programmed cell death, is now emerging as a crucial mechanism for cell survival in response to a variety of cell stressors, including nutrient deprivation, damage of cytoplasmic organelles, or accumulation of misfolded proteins. Impairment of autophagic flux in neurons often associates with neurodegeneration during cerebral amyloidosis, suggesting a role in clearing neurons from aggregation-prone misfolded proteins. Thus, autophagy may represent a target for innovative therapies. In this work, we show that alterations of autophagy progression occur in neurons following in vitro exposure to the amyloidogenic and neurotoxic prion protein-derived peptide PrP90-231. We report that the increase of autophagic flux represents a strategy adopted by neurons to survive the intracellular accumulation of misfolded PrP90-231. In particular, PrP90-231 internalization in A1 murine mesencephalic neurons occurs in acidic structures, showing electron microscopy hallmarks of autophagosomes and autophagolysosomes. However, these structures do not undergo resolution and accumulate in cytosol, suggesting that, in the presence of PrP90-231, autophagy is activated but its progression is impaired; the inability to clear PrP90-231 via autophagy induces cytotoxicity, causing impairment of lysosomal integrity and cytosolic diffusion of hydrolytic enzymes. Conversely, the induction of autophagy by pharmacological  blockade of mTOR kinase or trophic factor deprivation restored autophagy resolution, reducing intracellular PrP90-231 accumulation and neuronal death. Taken together, these data indicate that PrP90-231 internalization induces an autophagic defensive response in A1 neurons, although incomplete and insufficient to grant survival; the pharmacological enhancement of this process exerts neuroprotection favoring the clearing of the internalized peptide and could represents a promising neuroprotective tool for neurodegenerative proteinopathies.

Indexed as

AutophagyProtein AggregatesProtein FoldingAcidsAnimalsAutophagosomesCytoplasmic VesiclesEndocytosisIntracellular SpaceLysosomesMembrane Potential, MitochondrialMiceMitochondriaNeuronsNeuroprotectionPeptidesAcidsPeptidesPrion ProteinsProtein AggregatesSirolimus

Identifiers

PMID29416016
PMCPMC5833808
OpenAlexW2789918852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.